TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: apnea hypopnea index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: correlation between full-scale IQ, sleep time and AHI
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Total Nasal Symptoms Score (iTNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of bleeding episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction of disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 6-minute Walk Test (6MWT) Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to clinical progression of amyloid symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Attachment Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interleukin-21(IL-21) Cytokine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Minimal Inter-incisor Opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall rate of incident delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to onset of incident delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate of ascites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abstinence at 12 months postpartum
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Self-reported clinical failure
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of residents receiving antipsychotic medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maternal Capacity for Reflective Functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of Maternal Representations of the Child
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of deep incisional SSI
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with adverse event (AE) to vancomycin
Endpoint domain: Adverse events/effects
Primary endpoint: induction and frequency of p53-specific T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of Subjects Alive Not on Vasopressors, Mechanical Ventilator, or Dialysis
Endpoint domain: Mortality/survival
Primary endpoint: Number of Subjects With SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Retention Feasibility
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean Change in Serum Sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma lipopolysaccharide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma lipopolysaccharide binding protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Soluble cluster of differentiation 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Soluble cluster of differentiation 163
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion rate of neutralizing antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: One-year ipsilateral stroke or death
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients developing symptomatic seroma requiring intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Change in aerobic capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Average Reflective Total Nasal Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving PediACR30 Response Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Eating Disorders Examination Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Irritable Bowel Syndrome Severity Scoring System (IBS-SSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Gastrointestinal Symptom Rating Scale - IBS version (GSRS-IBS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Presence of positive mental health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Standard deviation of steering error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spatial auditory performances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lupus anticoagulant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anticardiolipin antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: B2 Glycoprotein I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in QoL as assessed by SF12
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in QoL as assessed by KCCQ
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in QoL as assessed by TASQ
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Arterial Target to Background Ratio of 18-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Intestinal Epithelial Integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Soluble CD14 Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Feasibility and accuracy of glucose detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic intracranial hemorrhage (sICH) within 36 hours
Endpoint domain: Adverse events/effects
Primary endpoint: Symptomatic intracerebral hemorrhage within 96 hours
Endpoint domain: Adverse events/effects
Primary endpoint: Weighted Mean Change in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Performance in LOCATO task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: rate of significant colon neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Amount of Olanzapine Co-medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline fMRI BOLD Activation Score in the Right VLPFC During Go/No-go Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline fMRI BOLD Activation Score in the Right VLPFC During SSRT Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of PSA elevation after DRE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular Death or Heart Failure Re-hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: patient's tolerance to the diet by week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Persisting hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Serum lactate concentration trend
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Radiographic Evidence of Disease Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regional distribution of pulmonary ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: changes of estimated GFR (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 50% eGFR decline or renal replacement therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Clinical Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neutrophil-Lymphocyte Ratio (NLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants Achieving Sustained Viral Response 12 Weeks After Completing Study Therapy (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing an Adverse Event (AE) During Treatment and First 14 Follow-up Days
Endpoint domain: Adverse events/effects
Primary endpoint: All-cause Mortality (ACM) Through Day 28
Endpoint domain: Mortality/survival
Primary endpoint: Time Required to Achieve Hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time Required From the Completion of the Ablation Portion of the Procedure Until the Patient Leaves the EP Lab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction of procoagulant microparticles concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total VTE and VTE-related death
Endpoint domain: Mortality/survival
Primary endpoint: Major and clinically relevant non major bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Time to the First Pulmonary Exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ultrasound image quality-resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrasound image quality-details
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrasound image quality-total image quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 6-minute walk test (6-MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of hospital stay following kidney transplantation
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Participant safety
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Peak VO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients with biopsy-proven acute rejection events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of mortality
Endpoint domain: Mortality/survival
Primary endpoint: Number of respiratory complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of cardiac complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of renal complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of thromboembolic complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of infectious complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of amputation
Endpoint domain: Mortality/survival
Primary endpoint: Mean Percentage of Correct Skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Confidence at 4 Months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent Change From Baseline in Practice of Oral Health Based on Pre and Post Study Chart Audit at 6 Months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Complete spontaneous bowel movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patient activation across time
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Negative Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Patients Maintaining Target/Adequate Mean Arterial Pressure (MAP>60 mmHg) Without Norepinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to Septic Shock Resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate (full, partial, non-responder)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in the total area of the GA lesion(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in C-peptide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in inflammation markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Perceived HIV-related Stigma
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Condom Use Self-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: recurrence of anal fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pharmacokinetics of 124I-hu3F8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to anxiety and/or depressive relapse
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean rate of change in the area of ellipsoid zone defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timely identification for need of palliative care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: pharmacokinetics of Rosiglitazone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Functional Assessment of Cancer Therapy - Breast Symptom Index (FACT-B)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Vasoconstrictor Responsiveness to Norepinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lamina Cribrosa Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child PTSD Symptom Scale for DSM-V
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mood and Feelings Questionnaire - Short
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Radiographically apparent fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to outreach intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in dietary habits
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rapid Eye Movement (REM) sleep latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total duration of Rapid Eye Movement (REM) sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total time spent in deep sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IgG levels to Rotavirus VP6 or Cryptosporidial Gp15
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prolongation of the honeymoon period in type 1 diabetic patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lymphedema symptom experience
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measured adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Penetration Aspiration Scale (PAS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of maximal oxygen uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Typical Weekend Drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Declining to Ride With Impaired Drivers
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: need for vascular surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: device failure
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of latent heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cmax: Maximum Plasma Concentration for TAK-536, Its Metabolites (M-I and M-II) and Hydrochlorothiazide (HCTZ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax: Maximum Plasma Concentration for Amlodipine Besilate (AML)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-48): Area Under the Plasma Concentration-Time Curve From Time 0 to 48 Hours Postdose for TAK-536, Its Metabolites (M-I and M-II) and HCTZ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of early gastric cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall post-operative complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of cardiac or device related clinic visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Insulin Secretory Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change from baseline in IBS-SSS questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: V02 max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exon inclusion mean level of messenger RNA leucocyte
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with provided care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Amino acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ghrelin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incretins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Symptoms and Complaints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Depressive Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in subjective stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in pulmonary function (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Facial pain scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of spasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Serum T3 and T4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Neck ultrasonography results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum D-dimer levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LGA newborns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Predefined Antibody Level for Diphtheria, Tetanus, and Acellular Pertussis Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Concentrations (GMC) for Diphtheria, Tetanus and Acellular Pertussis Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Ratio (GMR) of post-vaccination versus pre-vaccination antibody concentrations against Diphtheria, Tetanus and Acellular Pertussis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Baseline LDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hospital Anxiety and Depression Scale (HADS) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Arterial Resistive Index (RI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patellar Tilt Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patellar Congruence Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tibial tuberosity-trochlear groove distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deep Sternal Wound Infection Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Brief Psychiatric Rating Scale (BPRS) Psychosis Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease of prosthetic micromotion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedure-related cardiac complication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound Infection at 48 hours
Endpoint domain: Adverse events/effects
Primary endpoint: Time Until a Patient is Ready for Discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital